{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:43:19Z","timestamp":1780065799093,"version":"3.54.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The appropriate use of recombinant human growth hormone (r-hGH) treatment provides an opportunity to improve growth outcomes among pediatric patients with growth hormone deficiency (GHD). However, a major challenge in clinical practice is to adequately recognize and address factors that negatively affect treatment adherence. TUITEK<jats:sup>\u00ae<\/jats:sup> patient support program (PSP) was designed to help caregivers of children diagnosed with GHD to personalize the care pathway, improve adherence, and achieve better outcomes. Effectiveness of TUITEK<jats:sup>\u00ae<\/jats:sup> PSP has been demonstrated previously in a smaller sample (n = 31) in Taiwanese population. Here, we present the results from Argentina.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>TUITEK<jats:sup>\u00ae<\/jats:sup> PSP was piloted among 76 caregivers of children with GHD administering r-hGH using easypod\u2122 (Merck KGaA, Darmstadt, Germany) auto-injector device in Argentina. Based on TUITEK<jats:sup>\u00ae<\/jats:sup> personalization questionnaire, caregivers were assigned to high- and low-risk groups across four categories that may influence adherence, including disease and treatment coherence (DTC), self-administration (SA), treatment-related anxiety (TRA), and emotional burden (EB). The caregivers who were included in atleast one high-risk group had the provision of telephone calls with a nurse practitioner every 2 weeks for 3 months. The Wilcoxon signed-rank test was employed to assess changes in questionnaire-based scoring patterns between baseline and follow-up evaluations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Statistically significant changes (<jats:italic>p<\/jats:italic> &amp;lt; 0.05) in questionnaire scores between baseline and follow-up evaluations were observed across the four categories. The mean\/median DTC (n = 11) and SA (n = 23) scores changed from 2.45\/3 and 2.17\/2, respectively, to 4\/4, with all the caregivers moving to low-risk group following program completion (100%) for both categories. The mean\/median TRA score (n = 40) changed from 3.58\/3 to 2.5\/2 and 67.5% of patients (27\/40) moved to low-risk group. The mean\/median EB score (n = 32) changed from 3.69\/3 to 3.13\/3 however, none of the caregivers moved to low-risk group (0%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TUITEK<jats:sup>\u00ae<\/jats:sup> PSP is a simple, practical, and time-efficient interventional tool that can be used to address key adherence-related issues among caregivers of children with GHD and provide personalized adherence support. Our findings demonstrate that TUITEK<jats:sup>\u00ae<\/jats:sup> PSP has the potential to improve treatment adherence and self-management, thereby improving growth outcomes in Argentina.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1129385","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T06:12:11Z","timestamp":1680761531000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating the TUITEK\u00ae patient support program in supporting caregivers of children diagnosed with growth hormone deficiency in Argentina"],"prefix":"10.3389","volume":"14","author":[{"given":"Aria Reza","family":"Assefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Lourdes","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Debicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Reston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit","family":"Jheeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Koledova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000350251","article-title":"Understanding the growth hormone therapy adherence paradigm: A systematic review","volume":"79","author":"Fisher","year":"2013","journal-title":"Horm Res Paediatr"},{"key":"B2","volume-title":"Human growth hormone (somatropin) for the treatment of growth failure in children","year":"2010"},{"key":"B3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00148581-200406020-00003","article-title":"Growth hormone treatment in children: Review of safety and efficacy","volume":"6","author":"Harris","year":"2004","journal-title":"Paediatr Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ecl.2009.06.006","article-title":"Growth hormone: The expansion of available products and indications","volume":"38","author":"Franklin","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4158\/EP13194.OR","article-title":"Adherence to growth hormone therapy: Results of a multicenter study","volume":"20","author":"Ayd\u0131n","year":"2014","journal-title":"Endocr Pract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S6525","article-title":"Somatotropin in the treatment of growth hormone deficiency and turner syndrome in pediatric patients: A review","volume":"2","author":"Reh","year":"2010","journal-title":"Clin Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1687-9856-2014-15","article-title":"Growth hormone significantly increases the adult height of children with idiopathic short stature: Comparison of subgroups and benefit","volume":"2014","author":"Sotos","year":"2014","journal-title":"Int J Pediatr Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta14420","article-title":"Recombinant human growth hormone for the treatment of growth disorders in children: A systematic review and economic evaluation","volume":"14","author":"Takeda","year":"2010","journal-title":"Health Technol Assess"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000493211","article-title":"Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: A systematic review","volume":"90","author":"Graham","year":"2018","journal-title":"Horm Res Paediatr"},{"key":"B10","first-page":"1","volume-title":"Investing in medication adherence improves health outcomes and health system efficiency: Adherence to medicines for diabetes, hypertension, and hyperlipidaemia","author":"Khan","year":"2018"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-017-0237-9","article-title":"Understanding treatment burden for children treated for growth hormone deficiency","volume":"10","author":"Brod","year":"2017","journal-title":"Patient"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2020-0543","article-title":"What potentially modifiable factors are associated with treatment nonadherence in pediatric growth hormone deficiency? a quantitative study","volume":"27","author":"Graham","year":"2021","journal-title":"Endocr Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/hex.12040","article-title":"Parents\u2019 experiences of living with a child with a long-term condition: A rapid structured review of the literature","volume":"18","author":"Smith","year":"2015","journal-title":"Health Expect"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2196\/32626","article-title":"Adherence to growth hormone treatment using a connected device in Latin America: Real-world exploratory descriptive analysis study","volume":"10","author":"Assefi","year":"2022","journal-title":"JMIR Mhealth Uhealth"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016223","article-title":"Non-compliance with growth hormone treatment in children is common and impairs linear growth","volume":"6","author":"Cutfield","year":"2011","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-1024","article-title":"Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: Analysis from NordiNet\u00ae international outcome study","volume":"177","author":"Polak","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000357975","article-title":"Adherence to growth hormone therapy: A practical approach","volume":"81","author":"Bozzola","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0172","article-title":"Adherence and long-term growth outcomes: Results from the easypod\u2122 connect observational study (ECOS) in paediatric patients with growth disorders","volume":"7","author":"Koledova","year":"2018","journal-title":"Endocr Connect"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S268972","article-title":"Exploring potentially modifiable factors that influence treatment non-adherence amongst pediatric growth hormone deficiency: A qualitative study","volume":"14","author":"Graham","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1529-1","article-title":"Understanding burden of illness for child growth hormone deficiency","volume":"26","author":"Brod","year":"2017","journal-title":"Qual Life Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S33157","article-title":"Parents\u2019 views on growth hormone treatment for their children: Psychosocial issues","volume":"6","author":"van Dongen","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"B22","doi-asserted-by":"publisher","first-page":"FSO82","DOI":"10.4155\/fso.15.82","article-title":"Stories of experiences of care for growth hormone deficiency: The CRESCERE project","volume":"2","author":"Marini","year":"2016","journal-title":"Future Sci OA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntq002","article-title":"Telephone-delivered acceptance and commitment therapy for adult smoking cessation: A feasibility study","volume":"12","author":"Bricker","year":"2010","journal-title":"Nicotine Tob Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2009.12.010","article-title":"Telephone nurse counseling for medication adherence in ulcerative colitis: A preliminary study","volume":"81","author":"Cook","year":"2010","journal-title":"Patient Educ Couns"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0738-3991(98)00098-6","article-title":"Using the telephone to improve health behavior and health service delivery","volume":"37","author":"McBride","year":"1999","journal-title":"Patient Educ Couns"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1037\/\/0022-006x.68.2.356","article-title":"Telephone-administered cognitive\u2013behavioral therapy for the treatment of depressive symptoms in multiple sclerosis","volume":"68","author":"Mohr","year":"2000","journal-title":"J Consult Clin Psychol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1037\/a0036322","article-title":"Telephone counseling and home telehealth monitoring to improve medication adherence: Results of a pilot trial among individuals with multiple sclerosis","volume":"59","author":"Turner","year":"2014","journal-title":"Rehabil Psychol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7370.925","article-title":"Interventions used in disease management programmes for patients with chronic illness-which ones work? meta-analysis of published reports","volume":"325","author":"Weingarten","year":"2002","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2021.609878","article-title":"Positive impact of targeted educational intervention in children with low adherence to growth hormone treatment identified by use of the easypod\u2122 electronic auto-injector device","volume":"3","author":"Assefi","year":"2021","journal-title":"Front Med Technol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.897956","article-title":"Investigating the impact of the TUITEK\u00ae patient support programme, designed to support caregivers of children prescribed recombinant human growth hormone treatment in Taiwan","volume":"13","author":"Su","year":"2022","journal-title":"Front Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12160-013-9486-6","article-title":"The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: Building an international consensus for the reporting of behavior change interventions","volume":"46","author":"Michie","year":"2013","journal-title":"Ann Behav Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1900","article-title":"Motivational interviewing","volume":"340","author":"Rollnick","year":"2010","journal-title":"BMJ"},{"key":"B33","article-title":"Health coaching for patients with chronic illness","volume":"17","author":"Bennett","year":"2010","journal-title":"Fam Pract Manag"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1159\/000437305","article-title":"Low treatment adherence in pubertal children treated with thyroxin or growth hormone","volume":"84","author":"Lass","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedn.2019.09.005","article-title":"Mothers\u2019 experiences of caring for children receiving growth hormone treatment","volume":"49","author":"Alsaigh","year":"2019","journal-title":"J Pediatr Nurs"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1129385\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T06:12:15Z","timestamp":1680761535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1129385\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":35,"alternative-id":["10.3389\/fendo.2023.1129385"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1129385","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"article-number":"1129385"}}